Non Embryonic Als Research Papers

Unless you are the self-proclaimed science nerd of your friend and family circle, most people don’t quite understand stem cell research and the ethical issues surrounding it.

If you try to learn more from Google, you will likely be bombarded by medical lingo until you feel immersed in a foreign language.

Have no fear, here’s the top 6 things you need to know about stem cell research to impress your science nerd friends.

1 What exactly is embryonic stem cell research?

Embryonic stem cell research usually begins when scientists manufacture conception within a lab.  Once conception has been manufactured, the tiny human is allowed to grow for about 3-5 days.  Then, the developing human is usually killed in order to harvest the stem cells for research.

2 Why is embryonic stem cell research unethical?

At conception this tiny human’s hair color, eye color, and sex have already been determined. The tiny human’s DNA is completely unique from the mother and father and will never again be repeated in the history of the human race. To conduct stem cell research, scientists have to stop that rapidly growing tiny human from developing – which otherwise left alone – would become a fully formed human being.  Remember, you and I started out this small too!

3 Is embryonic stem cell research successful?

Not exactly. Not only is it very controversial, it has been found highly ineffective as well.  Adult stem cell research has been found to be significantly more successful.

4 So Adult Stem Cell research is ethical, right?

Not so fast. Most of adult stem cell research is ethical and shows very encouraging results to cure neurological diseases. However the word “adult” in stem cell research is used to describe the age of the cell not the age of the person its is taken from. Therefore, adult stem cells can also be used to describe cells taken from an aborted child.

5 Why exactly does Illinois Right to Life discourage donating to the ALS Association?

The ALS Association admitted they are currently conducting a research project using embryonic stem cells. Also, the ALS Association gave approximately $500,000.00 to the research group NEALS, which conducted research using cells from an 8-week-old aborted child. At 8 weeks, an unborn child’s heart is beating about 100 times a minute and s/he is already dancing in the womb. While his or her fingers and toes are still a bit webbed, the eyelids are now almost fully covering his or her eyes.

Good alternatives are The John Paul II Medical Research Institute, or Research Downs Syndrome (in an email to us, staff confirmed that grants issue by the organization specifically state “no embryonic stem cell research”).

6 Should I even participate in the ALS Ice Bucket Challenge?

YES! What, are you afraid of a little ice water? Participate, but in your video state that you love and respect all human life too much, so you are donating to an organization that supports research that benefits all human life – not research that destroys human life.

If science tells us that we need to destroy one human to cure another then they have failed us.
We can do better than that.

Let’s work towards creating a medical society that values every human equally regardless of size rather than a medical society that destroys one human in an attempt to save another.

This entry was posted in Blog by dbrindle. Bookmark the permalink.

1. Gordon PH. Amyotrophic Lateral Sclerosis: An update for 2013 Clinical Features, Pathophysiology, Management and Therapeutic Trials. Aging Dis. 2013;4(5):295–310. doi: 10.14336/AD.2013.0400295.[PMC free article][PubMed][Cross Ref]

2. Chio A, Logroscino G, Traynor BJ, Collins J, Simeone JC, Goldstein LA, White LA. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology. 2013;41(2):118–130. doi: 10.1159/000351153.[PMC free article][PubMed][Cross Ref]

3. Marin B, Gil J, Preux PM, Funalot B, Couratier P. Incidence of amyotrophic lateral sclerosis in the Limousin region of France, 1997-2007. Amyotroph Lateral Scler. 2009;10(4):216–220. doi: 10.1080/17482960902721626.[PubMed][Cross Ref]

4. Swinnen B, Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nat Rev Neurol. 2014;10(11):661–670. doi: 10.1038/nrneurol.2014.184.[PubMed][Cross Ref]

5. D'Amico E, Factor-Litvak P, Santella RM, Mitsumoto H. Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radic Biol Med. 2013;65:509–527. doi: 10.1016/j.freeradbiomed.2013.06.029.[PMC free article][PubMed][Cross Ref]

6. Mancuso R, Navarro X. Amyotrophic lateral sclerosis: Current perspectives from basic research to the clinic. Prog Neurobiol. 2015;133:1–26. doi: 10.1016/j.pneurobio.2015.07.004.[PubMed][Cross Ref]

7. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) Cochrane Database Syst Rev. 2012;3:CD001447. doi: 10.1002/14651858.cd001447.pub3.[PubMed][Cross Ref]

8. Miller RG, Rosenberg JA, Gelinas DF, Mitsumoto H, Newman D, Sufit R, Borasio GD. et al. Practice parameter: The care of the patient with amyotrophic lateral sclerosis (An evidence-based review) Muscle Nerve. 1999;22(8):1104–1118. doi: 10.1002/(SICI)1097-4598(199908)22:8<1104::AID-MUS15>3.0.CO;2-2.[PubMed][Cross Ref]

9. Lunn JS, Sakowski SA, Feldman EL. Concise review: Stem cell therapies for amyotrophic lateral sclerosis: recent advances and prospects for the future. Stem Cells. 2014;32(5):1099–1109. doi: 10.1002/stem.1628.[PMC free article][PubMed][Cross Ref]

10. Ludolph A, Drory V, Hardiman O, Nakano I, Ravits J, Robberecht W, Shefner J. A revision of the El Escorial criteria - 2015. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5-6):291–292. doi: 10.3109/21678421.2015.1049183.[PubMed][Cross Ref]

11. Costa J, Swash M, de Carvalho M. Awaji criteria for the diagnosis of amyotrophic lateral sclerosis:a systematic review. Arch Neurol. 2012;69(11):1410–1416. doi: 10.1001/archneurol.2012.254.[PubMed][Cross Ref]

12. Puhan MA, Schunemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh JA, Kessels AG. et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ. 2014;349:g5630. doi: 10.1136/bmj.g5630.[PubMed][Cross Ref]

13. Gu R, Hou X, Pang R, Li L, Chen F, Geng J, Xu Y. et al. Human adipose-derived stem cells enhance the glutamate uptake function of GLT1 in SOD1(G93A)-bearing astrocytes. Biochem Biophys Res Commun. 2010;393(3):481–486. doi: 10.1016/j.bbrc.2010.02.029.[PubMed][Cross Ref]

14. Xu L, Shen P, Hazel T, Johe K, Koliatsos VE. Dual transplantation of human neural stem cells into cervical and lumbar cord ameliorates motor neuron disease in SOD1 transgenic rats. Neurosci Lett. 2011;494(3):222–226. doi: 10.1016/j.neulet.2011.03.017.[PMC free article][PubMed][Cross Ref]

15. Boido M, Piras A, Valsecchi V, Spigolon G, Mareschi K, Ferrero I, Vizzini A. et al. Human mesenchymal stromal cell transplantation modulates neuroinflammatory milieu in a mouse model of amyotrophic lateral sclerosis. Cytotherapy. 2014;16(8):1059–1072. doi: 10.1016/j.jcyt.2014.02.003.[PubMed][Cross Ref]

16. Dadon-Nachum M, Ben-Yaacov K, Ben-Zur T, Barhum Y, Yaffe D, Perlson E, Offen D. Transplanted modified muscle progenitor cells expressing a mixture of neurotrophic factors delay disease onset and enhance survival in the SOD1 mouse model of ALS. J Mol Neurosci. 2015;55(3):788–797. doi: 10.1007/s12031-014-0426-0.[PubMed][Cross Ref]

17. Kim H, Kim HY, Choi MR, Hwang S, Nam KH, Kim HC, Han JS. et al. Dose-dependent efficacy of ALS-human mesenchymal stem cells transplantation into cisterna magna in SOD1-G93A ALS mice. Neurosci Lett. 2010;468(3):190–194. doi: 10.1016/j.neulet.2009.10.074.[PubMed][Cross Ref]

18. Bigini P, Veglianese P, Andriolo G, Cova L, Grignaschi G, Caron I, Daleno C. et al. Intracerebroventricular administration of human umbilical cord blood cells delays disease progression in two murine models of motor neuron degeneration. Rejuvenation Res. 2011;14(6):623–639. doi: 10.1089/rej.2011.1197.[PubMed][Cross Ref]

19. Uccelli A, Milanese M, Principato MC, Morando S, Bonifacino T, Vergani L, Giunti D. et al. Intravenous mesenchymal stem cells improve survival and motor function in experimental amyotrophic lateral sclerosis. Mol Med. 2012;18:794–804. doi: 10.2119/molmed.2011.00498.[PMC free article][PubMed][Cross Ref]

20. Kondo T, Funayama M, Tsukita K, Hotta A, Yasuda A, Nori S, Kaneko S. et al. Focal transplantation of human iPSC-derived glial-rich neural progenitors improves lifespan of ALS mice. Stem Cell Reports. 2014;3(2):242–249. doi: 10.1016/j.stemcr.2014.05.017.[PMC free article][PubMed][Cross Ref]

21. Garbuzova-Davis S, Rodrigues MC, Mirtyl S, Turner S, Mitha S, Sodhi J, Suthakaran S. et al. Multiple intravenous administrations of human umbilical cord blood cells benefit in a mouse model of ALS. PLoS One. 2012;7(2):e31254. doi: 10.1371/journal.pone.0031254.[PMC free article][PubMed][Cross Ref]

22. Hefferan MP, Galik J, Kakinohana O, Sekerkova G, Santucci C, Marsala S, Navarro R. et al. Human neural stem cell replacement therapy for amyotrophic lateral sclerosis by spinal transplantation. PLoS One. 2012;7(8):e42614. doi: 10.1371/journal.pone.0042614.[PMC free article][PubMed][Cross Ref]

23. Lee HJ, Kim KS, Ahn J, Bae HM, Lim I, Kim SU. Human motor neurons generated from neural stem cells delay clinical onset and prolong life in ALS mouse model. PLoS One. 2014;9(5):e97518. doi: 10.1371/journal.pone.0097518.[PMC free article][PubMed][Cross Ref]

24. Lee JC, Seong J, Kim SH, Lee SJ, Cho YJ, An J, Nam DH. et al. Replacement of microglial cells using Clodronate liposome and bone marrow transplantation in the central nervous system of SOD1(G93A) transgenic mice as an in vivo model of amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2012;418(2):359–365. doi: 10.1016/j.bbrc.2012.01.026.[PubMed][Cross Ref]

25. Sun H, Hou Z, Yang H, Meng M, Li P, Zou Q, Yang L. et al. Multiple systemic transplantations of human amniotic mesenchymal stem cells exert therapeutic effects in an ALS mouse model. Cell Tissue Res. 2014;357(3):571–582. doi: 10.1007/s00441-014-1903-z.[PubMed][Cross Ref]

26. Nizzardo M, Simone C, Rizzo F, Ruggieri M, Salani S, Riboldi G, Faravelli I. et al. Minimally invasive transplantation of iPSC-derived ALDHhiSSCloVLA4+ neural stem cells effectively improves the phenotype of an amyotrophic lateral sclerosis model. Hum Mol Genet. 2014;23(2):342–354. doi: 10.1093/hmg/ddt425.[PMC free article][PubMed][Cross Ref]

27. Martinez HR, Gonzalez-Garza MT, Moreno-Cuevas JE, Caro E, Gutierrez-Jimenez E, Segura JJ. Stem-cell transplantation into the frontal motor cortex in amyotrophic lateral sclerosis patients. Cytotherapy. 2009;11(1):26–34. doi: 10.1080/14653240802644651.[PubMed][Cross Ref]

28. Mazzini L, Mareschi K, Ferrero I, Miglioretti M, Stecco A, Servo S, Carriero A. et al. Mesenchymal stromal cell transplantation in amyotrophic lateral sclerosis: a long-term safety study. Cytotherapy. 2012;14(1):56–60. doi: 10.3109/14653249.2011.613929.[PubMed][Cross Ref]

29. Deda H, Inci MC, Kurekci AE, Sav A, Kayihan K, Ozgun E, Ustunsoy GE. et al. Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: a 1-year follow-up. Cytotherapy. 2009;11(1):18–25. doi: 10.1080/14653240802549470.[PubMed][Cross Ref]

30. Gamez J, Carmona F, Raguer N, Ferrer-Sancho J, Martin-Henao GA, Marti-Beltran S, Badia M. et al. Cellular transplants in amyotrophic lateral sclerosis patients: an observational study. Cytotherapy. 2010;12(5):669–677. doi: 10.3109/14653241003774037.[PubMed][Cross Ref]

31. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori JM, Kassis I, Bulte JW. et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol. 2010;67(10):1187–1194. doi: 10.1001/archneurol.2010.248.[PMC free article][PubMed][Cross Ref]

32. Tarella C, Rutella S, Gualandi F, Melazzini M, Scime R, Petrini M, Moglia C. et al. Consistent bone marrow-derived cell mobilization following repeated short courses of granulocyte-colony-stimulating factor in patients with amyotrophic lateral sclerosis: results from a multicenter prospective trial. Cytotherapy. 2010;12(1):50–59. doi: 10.3109/14653240903300682.[PubMed][Cross Ref]

33. Glass JD, Boulis NM, Johe K, Rutkove SB, Federici T, Polak M, Kelly C. et al. Lumbar intraspinal injection of neural stem cells in patients with amyotrophic lateral sclerosis: results of a phase I trial in 12 patients. Stem Cells. 2012;30(6):1144–1151. doi: 10.1002/stem.1079.[PubMed][Cross Ref]

34. Riley J, Glass J, Feldman EL, Polak M, Bordeau J, Federici T, Johe K. et al. Intraspinal stem cell transplantation in amyotrophic lateral sclerosis: a phase I trial, cervical microinjection, and final surgical safety outcomes. Neurosurgery. 2014;74(1):77–87. doi: 10.1227/NEU.0000000000000156.[PubMed][Cross Ref]

35. Riley J, Federici T, Polak M, Kelly C, Glass J, Raore B, Taub J. et al. Intraspinal stem cell transplantation in amyotrophic lateral sclerosis: a phase I safety trial, technical note, and lumbar safety outcomes. Neurosurgery. 2012;71(2):405–416. doi: 10.1227/NEU.0b013e31825ca05f. discussion 416. [PubMed][Cross Ref]

36. Sharma AK, Sane HM, Paranjape AA, Gokulchandran N, Nagrajan A, D'sa M, Badhe PB. The effect of autologous bone marrow mononuclear cell transplantation on the survival duration in Amyotrophic Lateral Sclerosis - a retrospective controlled study. Am J Stem Cells. 2015;4(1):50–65.[PMC free article][PubMed]

37. Blanquer M, Moraleda JM, Iniesta F, Gomez-Espuch J, Meca-Lallana J, Villaverde R, Perez-Espejo MA. et al. Neurotrophic bone marrow cellular nests prevent spinal motoneuron degeneration in amyotrophic lateral sclerosis patients: a pilot safety study. Stem Cells. 2012;30(6):1277–1285. doi: 10.1002/stem.1080.[PubMed][Cross Ref]

38. Prabhakar S, Marwaha N, Lal V, Sharma RR, Rajan R, Khandelwal N. Autologous bone marrow-derived stem cells in amyotrophic lateral sclerosis: a pilot study. Neurol India. 2012;60(5):465–469. doi: 10.4103/0028-3886.103185.[PubMed][Cross Ref]

39. Feldman EL, Boulis NM, Hur J, Johe K, Rutkove SB, Federici T, Polak M. et al. Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: phase 1 trial outcomes. Ann Neurol. 2014;75(3):363–373. doi: 10.1002/ana.24113.[PMC free article][PubMed][Cross Ref]

40. McDonald JW, Liu XZ, Qu Y, Liu S, Mickey SK, Turetsky D, Gottlieb DI. et al. Transplanted embryonic stem cells survive, differentiate and promote recovery in injured rat spinal cord. Nat Med. 1999;5(12):1410–1412. doi: 10.1038/70986.[PubMed][Cross Ref]

41. Coatti GC, Beccari MS, Olavio TR, Mitne-Neto M, Okamoto OK, Zatz M. Stem cells for amyotrophic lateral sclerosis modeling and therapy: myth or fact? Cytometry A. 2015;87(3):197–211. doi: 10.1002/cyto.a.22630.[PubMed][Cross Ref]

42. Perrin S. Preclinical research: Make mouse studies work. Nature. 2014;507(7493):423–425. doi: 10.1038/507423a.[PubMed][Cross Ref]

43. Ince PG, Highley JR, Kirby J, Wharton SB, Takahashi H, Strong MJ, Shaw PJ. Molecular pathology and genetic advances in amyotrophic lateral sclerosis: an emerging molecular pathway and the significance of glial pathology. Acta Neuropathol. 2011;122(6):657–671. doi: 10.1007/s00401-011-0913-0.[PubMed][Cross Ref]

44. Blokhuis AM, Groen EJ, Koppers M, van den Berg LH, Pasterkamp RJ. Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol. 2013;125(6):777–794. doi: 10.1007/s00401-013-1125-6.[PMC free article][PubMed][Cross Ref]

45. Vercelli A, Mereuta OM, Garbossa D, Muraca G, Mareschi K, Rustichelli D, Ferrero I. et al. Human mesenchymal stem cell transplantation extends survival, improves motor performance and decreases neuroinflammation in mouse model of amyotrophic lateral sclerosis. Neurobiol Dis. 2008;31(3):395–405. doi: 10.1016/j.nbd.2008.05.016.[PubMed][Cross Ref]

46. Mackay-Sim A, St John JA. Olfactory ensheathing cells from the nose: clinical application in human spinal cord injuries. Exp Neurol. 2011;229(1):174–180. doi: 10.1016/j.expneurol.2010.08.025.[PubMed][Cross Ref]

47. Huang H, Chen L, Xi H, Wang H, Zhang J, Zhang F, Liu Y. Fetal olfactory ensheathing cells transplantation in amyotrophic lateral sclerosis patients: a controlled pilot study. Clin Transplant. 2008;22(6):710–718. doi: 10.1111/j.1399-0012.2008.00865.x.[PubMed][Cross Ref]

48. Gourronc FA, Klingelhutz AJ. Therapeutic opportunities: telomere maintenance in inducible pluripotent stem cells. Mutat Res. 2012;730(1-2):98–105. doi: 10.1016/j.mrfmmm.2011.05.008.[PMC free article][PubMed][Cross Ref]

49. Ludolph AC, Bendotti C, Blaugrund E, Chio A, Greensmith L, Loeffler JP, Mead R. et al. Guidelines for preclinical animal research in ALS/MND: A consensus meeting. Amyotroph Lateral Scler. 2010;11(1-2):38–45. doi: 10.3109/17482960903545334.[PubMed][Cross Ref]

One thought on “Non Embryonic Als Research Papers

Leave a Reply

Your email address will not be published. Required fields are marked *